The overall survival, or OS rates, in the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd), did not ...
The US FDA has granted approval for AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for ...
AstraZeneca's cancer drug, datopotamab deruxtecan, failed to meet targets in a Phase 3 trial, clouding the possibility of approval from the U.S. Food and Drug Administration. Shares were down 1.2% at ...